CLINICAL TRIALS PROFILE FOR BRAFTOVI

All Clinical Trials for Braftovi

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02902042 ↗	Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma	Completed	Prof. Dr. med. Dirk Schadendorf	Phase 1/Phase 2	2018-04-24	This study will investigate the influence of maintenance therapy on progression-free survival (PFS) and overall survival (OS) after combination therapy with BRAF/MEK (MAP-ERK kinase) inhibitors and PD-1 antibody pembrolizumab. In the safety phase I part the optimal dose of pembrolizumab in combination with BRAF inhibitor and MEK inhibitor and the safety of this three-drugs-combination regime will be determined. In the randomized part 2 different maintenance therapies will be tested for toxicity and efficacy. Patients with disease control after 6 months of triple therapy will be randomized to receive 2 different maintenance therapies further on, either continuation of triple therapy or administration of pembrolizumab alone.
NCT02910700 ↗	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	Recruiting	Bristol-Myers Squibb	Phase 2	2016-12-09	This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Trametinib, dabrafenib, encorafenib, and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib may work better in treating patients with BRAF-mutated melanoma.
NCT02910700 ↗	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2016-12-09	This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Trametinib, dabrafenib, encorafenib, and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib may work better in treating patients with BRAF-mutated melanoma.
NCT02910700 ↗	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	Recruiting	M.D. Anderson Cancer Center	Phase 2	2016-12-09	This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Trametinib, dabrafenib, encorafenib, and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib may work better in treating patients with BRAF-mutated melanoma.
NCT03898908 ↗	Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain	Recruiting	MFAR	Phase 2	2019-07-18	Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.

Clinical Trial Conditions for Braftovi

Condition Name

Condition Name for Braftovi
Intervention	Trials
Melanoma	4
Metastatic Melanoma	4
Metastatic Rectal Adenocarcinoma	3
Metastatic Colon Adenocarcinoma	3

Condition MeSH

Condition MeSH for Braftovi
Intervention	Trials
Melanoma	10
Colorectal Neoplasms	5
Neoplasms	4
Colonic Neoplasms	4

Clinical Trial Locations for Braftovi

Trials by Country

Trials by Country for Braftovi
Location	Trials
United States	63
Germany	17
Spain	12
Italy	7
Czechia	5

Trials by US State

Trials by US State for Braftovi
Location	Trials
California	6
Texas	6
Michigan	4
Oregon	3
Ohio	3

Clinical Trial Progress for Braftovi

Clinical Trial Phase

Clinical Trial Phase for Braftovi
Clinical Trial Phase	Trials
Phase 3	2
Phase 2/Phase 3	1
Phase 2	10

Clinical Trial Status

Clinical Trial Status for Braftovi
Clinical Trial Phase	Trials
Recruiting	11
Not yet recruiting	7
Active, not recruiting	1

Clinical Trial Sponsors for Braftovi

Sponsor Name

Sponsor Name for Braftovi
Sponsor	Trials
National Cancer Institute (NCI)	9
Pfizer	5
M.D. Anderson Cancer Center	3

Sponsor Type

Sponsor Type for Braftovi
Sponsor	Trials
Other	25
Industry	19
NIH	9

Clinical Trials Update, Market Analysis, and Projections for BRAFTOVI

Last updated: October 29, 2025

Introduction

BRAFTOVI (encorafenib) is a targeted therapy developed by Classen Immunotherapies and marketed by Pfizer. Approved for the treatment of advanced melanoma with BRAF V600E or V600K mutations, BRAFTOVI exemplifies the expanding landscape of precision oncology. This article provides a comprehensive update on its ongoing clinical trials, assesses its current market positioning, and offers projections grounded in recent developments and strategic insights.

Clinical Trials Update

Regulatory Approvals and Current Indications

Since its FDA approval in 2018 for unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, BRAFTOVI has gained further indications. Notably, in combination with MEK inhibitors, the drug shows enhanced efficacy, with the FDA approving the combination with Mektovi (binimetinib) in 2020 for similar indications. These combination therapies leverage synergistic targeting of the MAPK pathway, substantially improving patient outcomes.

Ongoing and Recent Clinical Trials

Pfizer continues to explore BRAFTOVI through multiple clinical trials aimed at broadening its application and understanding resistance mechanisms. Recent data have emerged from studies such as:

• BREAK-3 (NCT01709419): Confirming efficacy and safety of BRAFTOVI monotherapy in advanced melanoma.
• COLUMBUS (NCT01909449): A phase III trial comparing encorafenib (BRAFTOVI) alone or with binimetinib versus vemurafenib. Results showed superior progression-free survival (PFS) with the combination.
• BEACON CRC (NCT02928224): A phase III trial evaluating encorafenib with cetuximab in BRAF V600E-mutant metastatic colorectal cancer, demonstrating promising activity.
• Adjuvant Trials: Pfizer is initiating studies like NCT03915951 assessing BRAFTOVI as adjuvant therapy in resected melanoma with BRAF mutations, potentially expanding its use to earlier disease stages.

Emerging Data and Resistance Mechanisms

Recent publications underscore challenges such as acquired resistance. Mechanisms include secondary mutations in the MAPK pathway and activation of alternative pathways like PI3K-AKT. Ongoing trials aim to counter resistance with triplet regimens combining BRAFTOVI, MEK inhibitors, and PI3K pathway antagonists.

Pediatric and Non-Oncologic Indications

Currently, BRAFTOVI’s age indications focus on adult patients. Nevertheless, preclinical studies investigate its applicability in pediatric melanoma and other rare BRAF-mutant tumors. FDA’s Pediatric Molecular Targeted Therapy Working Group is advancing trials to assess safety and efficacy in younger cohorts.

Market Analysis

Current Market Landscape

The global BRAF inhibitor market, valued at approximately USD 1.2 billion in 2022, is fueled by increasing melanoma incidence and expanding indications for BRAFTOVI and similar agents like vemurafenib (Zelboraf) and dabrafenib (Tafinlar). Pfizer’s BRAFTOVI maintains a competitive edge due to its favorable safety profile, oral administration, and proven efficacy, especially in combination with MEK inhibitors.

Competitive Positioning

BRAFTOVI’s main competitors include:

• Vemurafenib (Zelboraf): Launched in 2011, with extensive clinical data but higher dermatologic toxicity.
• Dabrafenib (Tafinlar): Approved in 2013, often combined with trametinib.
• Encorafenib + Binimetinib (Mektovi): Approved for first-line treatment, showing superior PFS compared to Vemurafenib.

Pfizer’s strategic emphasis on combination therapies and subsequent indications solidifies its position. The drug’s safety profile and efficacy in overcoming resistance are key differentiators.

Market Drivers and Limitations

Drivers:

• Rising melanoma biopsy rates enabling personalized therapy.
• Approval of combination regimens boosting treatment efficacy.
• Growing focus on targeted therapies in metastatic settings.

Limitations:

• Resistance development limits long-term effectiveness.
• Competition from immunotherapies, notably checkpoint inhibitors like pembrolizumab, which remain frontline options.
• High costs associated with targeted therapies constrain patient access and healthcare budgets.

Geographical and Demographic Market Dynamics

North America leads the market, driven by high melanoma incidence and advanced healthcare infrastructure. Europe follows, with increased adoption of targeted therapies. Emerging markets in Asia-Pacific are gaining momentum, supported by expanding oncology infrastructure and increasing awareness.

Forecast and Growth Projections

Analysts project the BRAF inhibitor market to reach USD 2.0 billion by 2027, with BRAFTOVI capturing a significant share due to its combination therapy approvals and ongoing trials. Notably:

• The expansion into earlier-stage disease and adjuvant settings could increase market penetration.
• Strategic collaborations with diagnostic developers for companion testing will bolster usage.
• Resistance management strategies are anticipated to sustain long-term sales flow.

Strategic Outlook and Future Projections

Pipeline and Innovation

Pfizer’s focus on combination regimens, including triplet therapies involving BRAFTOVI, MEK inhibitors, and immunotherapy agents, aims to extend treatment durability. Emerging data from trials assessing BRAFTOVI in other malignancies such as colorectal and thyroid cancers suggest potential new avenues.

Regulatory and Commercial Outlook

Regulatory authorities worldwide remain receptive to expanding indications, provided robust trial data. The trend toward personalized medicine supports BRAFTOVI's role in tailored treatment algorithms. Commercial success hinges on:

• Demonstrating superiority or non-inferiority to existing therapies.
• Managing resistance mechanisms.
• Cost-optimization strategies to improve accessibility.

Risks and Challenges

• Resistance development risks diminishing long-term efficacy.
• Competition from immunotherapies and biosimilars.
• Regulatory hurdles in expanding indications.
• Market saturation in developed regions.

Key Takeaways

• Ongoing Trials: Pfizer is actively exploring BRAFTOVI for broader indications, including adjuvant therapy and other cancer types, with promising early-phase data supporting expansion.
• Market Dynamics: The drug maintains a competitive position through its combination regimens, though competition remains intense from established and emerging therapies.
• Growth Potential: Anticipated to reach USD 2 billion by 2027 due to combination therapy approvals, with rising adoption in early-stage disease.
• Challenges: Resistance mechanisms and competition from immunotherapies may impact long-term market share.
• Strategic Focus: Continued innovation, strategic partnerships, and real-world evidence generation will be critical for sustained growth.

FAQs

Q1. What are the key clinical benefits of BRAFTOVI?
BRAFTOVI offers targeted inhibition of BRAF V600 mutations, leading to significant tumor reduction and improved progression-free survival, especially when combined with MEK inhibitors. Its oral administration enhances patient convenience.

Q2. How does BRAFTOVI compare with other BRAF inhibitors?
BRAFTOVI demonstrates a favorable safety profile and has shown superior efficacy in combination regimens compared to some rivals like vemurafenib, notably in resistance management and long-term outcomes.

Q3. What emerging indications could expand BRAFTOVI’s market?
Potential expansion includes adjuvant therapy in resected melanoma, treatment in other BRAF-mutant cancers (e.g., colorectal, thyroid), and pediatric indications, pending successful clinical trial outcomes.

Q4. What are the main resistance challenges associated with BRAFTOVI?
Resistance often arises via secondary mutations in the MAPK pathway or activation of alternative signaling pathways such as PI3K-AKT, necessitating combination therapies or novel agents to sustain efficacy.

Q5. How does Pfizer plan to sustain BRAFTOVI’s growth in a competitive landscape?
Through expanding indications, developing combination regimens incorporating immunotherapy, investing in resistance research, and strategic collaborations, Pfizer aims to maintain and grow BRAFTOVI’s market share.

---

Sources

1. FDA Drugs Approved in 2018. U.S. Food and Drug Administration.
2. Pfizer Official Website. BRAFTOVI and Mektovi prescribing information.
3. ClinicalTrials.gov. Various ongoing and completed trials involving encorafenib.
4. GlobalData Market Reports. Oncology targeted therapy market analysis (2022).
5. Journal of Clinical Oncology. Resistance mechanisms in BRAF-mutant cancers (2022).